By Vince Paolizzi, Director of NanoCool Sales, Peli BioThermal
Published in: pharmaceuticalonline.com
Published on: May 11, 2022
Vaporized liquid nitrogen is currently the only workable means of maintaining the ultra-cold temperatures necessary for certain therapeutics and tissue samples. While dry ice is a feasible solution for keeping packages between -20 and -80 C°, colder applications often necessitate the use of liquid nitrogen. This paradigm has resulted in a number of logistical challenges for biopharmaceutical companies, clinical trial sponsors, and healthcare providers, as both the temperature requirements for COVID-19 vaccines and the increasing proliferation of temperature-sensitive biotherapeutics has made ultra-cold storage capacity more critical than ever.
